Jazz Pharmaceuticals Announces Third Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Wall Street ends higher as tech rebounds before Nvidia results
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Dick's Sporting Goods (DKS) Misses Q2 EPS by 25c, Offers Guidance
Jazz Pharmaceuticals (JAZZ) Tops Q3 EPS by 23c
November 2, 2020 4:32 PM ESTJazz Pharmaceuticals (NASDAQ: JAZZ) reported Q3 EPS of $4.31, $0.23 better than the analyst estimate of $4.08. Revenue for the quarter came in at $600.89 million versus the consensus estimate of $577.58 million.
"We delivered strong financial results this quarter, with increasingly diversified revenues fueled by the recent launch of Zepzelca, an innovative new treatment for relapsed small cell lung cancer, which we expect to be a catalyst for significant... More
